Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Fluticasone furoate nasal spray in the treatment of allergic rhinitis

Authors Giavina-Bianchi P, Agondi R, Stelmach R, Cukier A, Kalil J

Published 11 April 2008 Volume 2008:4(2) Pages 465—472

DOI https://doi.org/10.2147/TCRM.S1984

Pedro Giavina-Bianchi1, Rosana Agondi1, Rafael Stelmach2, Alberto Cukier2, Jorge Kalil1

1Division of Clinical Immunology and Allergy, University of São Paulo, São Paulo, Brazil; 2Pulmonary Division, University of São Paulo, São Paulo, Brazil

Abstract: Allergic rhinitis (AR) is a prevalent disease with great morbidity and significant societal and economic burden. Intranasal corticosteroids are recommended as first-line therapy for patients with moderate-to-severe disease, especially when nasal congestion is a major component of symptoms. To compare the efficacy and safety profile of different available intranasal corticosteroids for the treatment of AR, it is important to understand their different structures and pharmacokinetic and pharmacodynamic properties. Knowledge of these drugs has increased tremendously over the last decade. Studies have elucidated mechanisms of action, pharmacologic properties, and the clinical impact of these drugs in allergic respiratory diseases. Although the existing intranasal corticosteroids are already highly efficient, the introduction of further improved formulations with a better efficacy/safety profile is always desired. Fluticasone furoate nasal spray is a new topical corticosteroid, with enhanced-affinity and a unique side-actuated delivery device. As it has high topical potency and low potential for systemic effects, it is a good candidate for rhinitis treatment.

Keywords: fluticasone furoate, corticosteroids, rhinitis, efficacy, safety, ARIA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Epileptic seizure after treatment with thiocolchicoside

Pedro Giavina-Bianchi, Mara Giavina-Bianchi, Luciana Kase Tanno, et al

Therapeutics and Clinical Risk Management 2009, 5:635-637

Published Date: 6 August 2009

Readers of this article also read:

Folate-modified lipid–polymer hybrid nanoparticles for targeted paclitaxel delivery

Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C, Kong D

International Journal of Nanomedicine 2015, 10:2101-2114

Published Date: 16 March 2015

Clinical utility of eslicarbazepine: current evidence

Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A

Drug Design, Development and Therapy 2015, 9:781-789

Published Date: 10 February 2015

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study

Azar ST, Hantash HA, Jambart S, El-Zaheri MM, Rachoin R, Chalfoun A, Lahoud L, Okkeh O, Bramlage P, Brudi P, Ambegaonkar BM

Vascular Health and Risk Management 2014, 10:225-235

Published Date: 7 May 2014

Molecular network topology and reliability for multipurpose diagnosis

Jalil MA, Moongfangklang N, Innate K, Mitatha S, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:2385-2392

Published Date: 19 October 2011

Suppression of IL-8 production from airway cells by tiotropium bromide in vitro

Suzaki I, Asano K, Shikama Y, Hamasaki T, Kanei A, Suzaki H

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:439-448

Published Date: 6 September 2011

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism

Alejandra Sekler, José M Jiménez, Leonel Rojo, Edgard Pastene, Patricio Fuentes, et al

Neuropsychiatric Disease and Treatment 2008, 4:715-722

Published Date: 8 August 2008

Clinical challenges in the management of osteoporosis

Sheryl F Vondracek, Paul Minne, Michael T McDermott

Clinical Interventions in Aging 2008, 3:315-329

Published Date: 6 June 2008

A gero-informatics tool to enhance the care of hospitalized older adults with cognitive impairment

Malaz Boustani, Stephanie Munger, Robin Beck, Noll Campbell, Michael Weiner

Clinical Interventions in Aging 2007, 2:247-253

Published Date: 15 July 2007